Dec 02, 2019 / 06:00PM GMT
Operator
Greetings and welcome to the KOL Call on Masitinib in Severe Asthma hosted by AB Science. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Alain Moussy, CEO of AB Science. Thank you, sir. You may begin.
Alain Moussy - AB Science S.A. - Co-Founder, Chairman, President, CEO & Scientific Director
Thank you. And welcome, ladies and gentlemen, to this web conference about the recent results of masitinib in severe asthma. It's my pleasure to welcome you and to present this data, will be -- and will present it in a structural way. So you have the agenda here on the screen. I will introduce, of course, the participants, in particular, the key opinion leader who will deliver this data. We will talk about the previous and these Phase III clinical results, and we'll discuss the masitinib positioning in the future. And then we'll leave it open for your questions.
Next slide. So with me, I will be assisted by 3 key opinion leader who know the masitinib clinical development in asthma.
AB Science SA on Masitinib in Severe Asthma - Conference Call Transcript
Dec 03, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers